Figure 5

(a) HUVEC viability and (b) MDA-MB-231 cell viability of non-drug-loaded Dex-SS-PAA NGs and Dex-MBA-PAA NGs. (c) HUVEC inhibition abilities and (d) MDA-MB-231 cell inhibition performance of free DOX, Dex-SS-PAA-DOX NGs and Dex-MBA-PAA-DOX NGs.